Bryn Mawr Capital Management LLC Sells 371 Shares of Novartis AG (NYSE:NVS)

Bryn Mawr Capital Management LLC cut its holdings in Novartis AG (NYSE:NVS) by 2.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,901 shares of the company’s stock after selling 371 shares during the period. Bryn Mawr Capital Management LLC’s holdings in Novartis were worth $1,303,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in NVS. Aaron Wealth Advisors LLC lifted its stake in Novartis by 9.2% in the third quarter. Aaron Wealth Advisors LLC now owns 4,854 shares of the company’s stock worth $494,000 after purchasing an additional 408 shares during the last quarter. Simplicity Solutions LLC raised its stake in shares of Novartis by 0.8% during the third quarter. Simplicity Solutions LLC now owns 44,965 shares of the company’s stock valued at $4,580,000 after acquiring an additional 342 shares during the last quarter. Patriot Financial Group Insurance Agency LLC raised its stake in shares of Novartis by 32.8% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 5,223 shares of the company’s stock valued at $532,000 after acquiring an additional 1,291 shares during the last quarter. Connecticut Wealth Management LLC bought a new position in shares of Novartis during the third quarter valued at about $242,000. Finally, Ballentine Partners LLC raised its stake in shares of Novartis by 7.5% during the third quarter. Ballentine Partners LLC now owns 11,253 shares of the company’s stock valued at $1,146,000 after acquiring an additional 783 shares during the last quarter. 13.12% of the stock is owned by institutional investors.

Novartis Price Performance

NVS stock opened at $97.44 on Friday. Novartis AG has a 1 year low of $92.19 and a 1 year high of $108.78. The company has a market cap of $199.17 billion, a P/E ratio of 13.15, a PEG ratio of 1.59 and a beta of 0.54. The firm has a 50-day moving average of $97.87 and a 200 day moving average of $98.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.90 and a quick ratio of 0.93.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Tuesday, January 30th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). The business had revenue of $11.42 billion during the quarter, compared to analysts’ expectations of $11.69 billion. Novartis had a return on equity of 32.15% and a net margin of 31.33%. During the same quarter last year, the company posted $1.51 EPS. On average, sell-side analysts forecast that Novartis AG will post 7.22 EPS for the current year.

Novartis Increases Dividend

The firm also recently disclosed an annual dividend, which was paid on Thursday, March 7th. Shareholders of record on Friday, March 8th were issued a $3.7772 dividend. This represents a yield of 3.1%. The ex-dividend date was Thursday, March 7th. This is a boost from Novartis’s previous annual dividend of $3.47. Novartis’s dividend payout ratio is 32.79%.

Analyst Ratings Changes

NVS has been the subject of several recent analyst reports. BMO Capital Markets upped their price objective on shares of Novartis from $114.00 to $116.00 and gave the company a “market perform” rating in a research note on Wednesday. Morgan Stanley started coverage on shares of Novartis in a research note on Tuesday, January 23rd. They issued an “equal weight” rating and a $114.00 price target for the company.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.